Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exodus, Surfer44 tipped me off to this stock. I like the video and what the CEO has to say, but I guess the one big question is Revenue once they commercialize their drugs. Do you or anyone have an estimated annual revenue number say for 2015 or 2016? Thanks
Awesome!
This baby is ready to fly again!
What do you mean?
Wheee!......Exersising rights.....Wheee!
Gap down today for what reasons? No reasons, just MMs play game.
Bad day today! The stock has broken the 61.8% fibo retracement level and it is on the verge of breaking a previous resistance of $14...not good..
Thanks for posting
CMBG is a strong buy!
tomorrow they will showcase 12 month KOA results – they will do this at the 2014 World Stem Cell Summit …
I think the results are very good … last insider trades were all buys … and why would the showcase bad results at the World Stem Cell Summit?
tomorrow we could see the next pop in the stock price!
What's your opinion on this puppy? Do you see any prospects of moving upwards?
11/14/2014 42,841
How much is short interest now?
short interest is normal 42k(http://www.nasdaq.com/symbol/cbmg/short-interest)
at the actual price it is really dangerous to short this stock!
insider trades are all buys 3/last three month (http://www.nasdaq.com/symbol/cbmg/insider-trades)
i think 12 month results will come this or next week
short numbers: 7/31/2014 --> 75,662 shares short
when they cover we are over 35 again!
Ringing the big bell.....No stopping them now....
Sell Orders not being filled... if you try selling on the ASK Good Luck getting filled I kept having to lower my ask and only getting partial fills got one fill for only 10 shares then someone keeps dropping the ask under me if you sell onto the bid the spread really sucks on this stock it was over 2$ a share spread ealier today beetween the bid and the ask but its all most like mission impossible to get filled on the ask and I would hate to try to have to sell in any size on this stock I have a very hard time getting filled on just a few 100 shares i couldnt imagine trying to sell like a 100k shares or something
Also company just spent a large portion of their cash and announced pretty big dilution 752,000 New Shares
Low Float:
Shares Outstanding: 7.58M
Float: 3.10M
(http://finance.yahoo.com/q/ks?s=CBMG)
tomorrow: bye bye shorters
it´s time to go long! the short play is over! Tomorrow they will get burned. In the evening we will see the short numbers. (http://www.nasdaq.com/symbol/cbmg/short-interest)
I think they will be over 100.000 and they won´t be able to cover under 30!!! low float ... big short squeeze is coming!!!
Down 20% ~ Ouch !
Bearish Three Gaps Up Pattern Formed ~
Sitting with free shares. I did take a few off the table at $36.50.
But I do have to agree with you somewhat, it is overbought. But I was also in agreement at $30! So maybe I am wrong!
CBMG
Negative News And It Crashes Like All Other Bio Tech Stocks. Careful At These High Prices ~
Way OverBought Sell Off Coming ~
Only 7.6 million shared outstanding, not a lot of shares out there,
Other side of coin bad news can drop it quickly and hard.
IMHO a forward split will have to be done when the product hits the market to raise capital cover marketing cost.
Current rise in price shows not to many shares out there to buy.
Not unless positive news of the KOA testing was leaked.
Low float stock is easy to manipulating the PPS. Today 's big up is unusual.
I am waiting for split to get in again.
Wait to they have a product,
I expect forward split soon.
Almost $30 this morning, wow!
CBMG
WOW this stock is crazy to up, even don't care about chart of overbought. No pull back. I am out with profits, but too early. I want to in again but no dip.
Have at it....Make yourself the moderator. Or you, gamood....Doll it up, since the info here is way way old.
I'm happy to see it can have some action, in the AH trading.
Might just be, that this thing gets gobbled up outright, by some much larger company, in the near future. Not sure which names might be interested their knee osteo research area.....
great stock!!! this could be a tenbagger within a year!
A revision of the description here on investorshub would be great! EBIG is dead - long live CBMG!
I am with you there, this has turned out to be my best investment ever!
Incredible....Maybe headed to 100$ status....I'm currently at over 10x profit....Amazing......
EBIG is dead long live CBMG
On Yahoo, people believe it will go $50 this year. They want to me sell $20 to them.
Currently at the top of the Fidelity market movers/gainers list, at +22.03% today......
WOW $20 coming in soon. This private investors already made 10mm+ profits.
No.....But if they're headed for legitamacy, it has been a painfully long process.
Can you say, you trust their complete abandonment of the original "goals" of EBIG, as in bringing small companies to full IPO status, for their new interest in biomed research?.....Without them ever saying, they've given up hope, on all previous ventures(wonder/tsingda/etc)?.....
Would you be ok, with them joining hands, with some medical marijuana "thing", next?.....
Sorry for calling it a "scam"....The latest news, and nasdaq compliance, sure point in the right direction....
I guess, time will tell.
Certainly happy to see the rise in PPS, so I hang in there, with my ancient shares....GLTA.
konshe
Don't you that your being a little rude.
You are joke. This stock will be reached $20 for sure.
Still think it a fraud?
See tomorrow PPS gap up on Nasdag market. See $20 this year soon.
Amazing increase....Too bad this stock is such an "unknown", or sleeper stock.....Maybe Nasdaq listing, will give them some notoriety or "presence", in the stock world....We shall see....
It looks we will trade at $10+ on the Nasdag Market.
Followers
|
35
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2750
|
Created
|
05/17/07
|
Type
|
Free
|
Moderators |
Cellular Biomedicine Group (NASDAQ: CBMG) is a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. We are the result of the acquisition, transfer, commercialization and advancement of thirty years of research and human treatment experience in cellular medicine. Our cellular research and development comes from collaboration among scientists and doctors from the US, Europe and China.
MARKET
Our primary target market is Greater China. Our first two therapy candidates are currently used to treat patients in research studies conducted in China. We are also engaged in a number of pre-clinical studies for other product or therapy candidates, which we believe have the potential to become safe and effective treatment options for a variety of degenerative and debilitating conditions. We believe that the results of our research studies will support expanded preclinical and clinical trials with a larger population of patients, which we expect to carry out through authorized treatment centers throughout Greater China. With the recent acquisition of AG, we added technical services revenue comprised of T Cells Receptor (“TCR”) clonality analysis technology and T Central Memory Cell (“Tcm”) and Dendritic Cell (“DC”) preparation methodologies.
Indication: Knee Osteoarthritis (KOA)
Technology Platform: Human Adipose-Derived Mesenchymal Progenitor Cells (haMPC)
Trial Phase: Clinical Trial Phase IIb, all patients completed treatment as of August 2014
Interim results from phase IIb clinical trial for KOA: klick here
Osteoarthritis is a degenerative disease of the joints. KOA is one of the most common types of osteoarthritis. Pathological manifestation of osteoarthritis is primarily local inflammation caused by immune response and subsequent damage of joints. Restoration of immune response and joint tissues are the objective of therapies.
According to International Journal of Rheumatic Diseases, 2011, 53% of KOA patients will degenerate to the point of disability. Conventional treatment usually involves invasive surgery with painful recovery and physical therapy. As drug-based methods of management are ineffective, the same journal estimates that some 1.5 million patients with this disability will degenerate to the point of requiring artificial joint replacement surgery every year. However, only 40,000 patients will actually be able to undergo replacement surgery, leaving the majority of patients to suffer from a life-long disability due to lack of effective treatment.
About haMPCs
haMPCs are currently being considered as a new and effective treatment for osteoarthritis, with a huge potential market. Osteoarthritis is one of the ten most disabling diseases in developed countries. Worldwide estimates are that 9.6% of men and 18.0% of women aged over 60 years have symptomatic osteoarthritis. It is estimated that the global OA therapeutics market was worth $4.4 billion in 2010 and is forecast to grow at a compound annual growth rate (“CAGR”) of 3.8% to reach $5.9 billion by 2018.
In order to bring haMPC-based KOA therapy to market, our market strategy is to: (a) establish regional laboratories that comply with cGMP standards in Shanghai and Beijing that meet Chinese regulatory approval; and (b) file joint applications with Class AAA hospitals (own commentary: press release from 09.02.2015 (klick here): We look forward to working with PLAGH as a long-term partner as we evaluate paths to commercialization,” commented Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.) to use haMPCs to treat KOA in a clinical trial setting.
Our KOA therapy is not surgically invasive – it uses a small amount (30ml) of adipose tissue obtained via liposuction from the patient, which is cultured and re-injected into the patient. The injections are designed to induce the body’s secretion of growth factors promoting immune response and regulation, and regrowth of cartilage. The down-regulation of the patient’s immune response is aimed at reducing and controlling inflammation which is a central cause of KOA.
We believe our proprietary method, subsequent haMPC proliferation and processing know-how will enable haMPC therapy to be a low cost and relatively safe and effective treatment for KOA. Additionally, banked haMPCs can continue to be stored for additional use in the future.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |